TY - JOUR
T1 - Sarcopenia measurement in research and clinical practice
AU - Dent, Elsa
AU - Woo, Jean
AU - Scott, David
AU - Hoogendijk, Emiel O.
PY - 2021/8
Y1 - 2021/8
N2 - Sarcopenia is a disease related to accelerated loss of skeletal muscle and subsequent decline in functional capacity. It affects approximately 13% of the world's population aged over 60 years. Sarcopenia is primarily managed and prevented through a combination of exercise prescription combined with appropriate nutritional strategies. This review outlines diagnostic and case finding/screening tools for age-related (primary) sarcopenia used in research and clinical practice. Diagnostic tools critically reviewed include those of the: European Workgroup for Sarcopenia (EWGSOP) versions 1 and 2; Asian Working Group for Sarcopenia (AWGS) versions 1 and 2; Foundation for the National Institutes of Health (FNIH); and the Sarcopenia Definition and Outcomes Consortium (SDOC). Criteria used by diagnostic tools (muscle mass, muscle strength and physical functioning/performance) are also detailed. Case-finding tools include the SARC-F questionnaire, Ishii's formula and Goodman's screening grid. Additionally, this review discusses the strengths and weaknesses of each diagnostic and case-finding tool, and examines their ability to reliably predict adverse clinical outcomes and patient responses to potential therapies.
AB - Sarcopenia is a disease related to accelerated loss of skeletal muscle and subsequent decline in functional capacity. It affects approximately 13% of the world's population aged over 60 years. Sarcopenia is primarily managed and prevented through a combination of exercise prescription combined with appropriate nutritional strategies. This review outlines diagnostic and case finding/screening tools for age-related (primary) sarcopenia used in research and clinical practice. Diagnostic tools critically reviewed include those of the: European Workgroup for Sarcopenia (EWGSOP) versions 1 and 2; Asian Working Group for Sarcopenia (AWGS) versions 1 and 2; Foundation for the National Institutes of Health (FNIH); and the Sarcopenia Definition and Outcomes Consortium (SDOC). Criteria used by diagnostic tools (muscle mass, muscle strength and physical functioning/performance) are also detailed. Case-finding tools include the SARC-F questionnaire, Ishii's formula and Goodman's screening grid. Additionally, this review discusses the strengths and weaknesses of each diagnostic and case-finding tool, and examines their ability to reliably predict adverse clinical outcomes and patient responses to potential therapies.
KW - 80 and over
KW - Aged
KW - Geriatric assessment/methods
KW - Sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85111378020&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1112672
UR - http://purl.org/au-research/grants/NHMRC/1123014
UR - http://purl.org/au-research/grants/NHMRC/1174886
U2 - 10.1016/j.ejim.2021.06.003
DO - 10.1016/j.ejim.2021.06.003
M3 - Review article
C2 - 34238636
AN - SCOPUS:85111378020
SN - 0953-6205
VL - 90
SP - 1
EP - 9
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
ER -